The Upcoming Specialty Medication Pipeline

The Upcoming Specialty Medication Pipeline

June 22, 2021

Scientific progress marches on. There are many specialty medications on the cusp of approval that are worth keeping an eye on in 2021, especially when it comes to specialty drugs for oncology, hematology, multiple sclerosis, and inflammatory diseases.

Oncology looks poised to be an area of particular significance. Last year, more than one-third of medication approvals were accounted for by oncology medications. This trend is expected to continue this year. In addition, numerous already approved specialty oncology medications are under review for approval for additional indications.

Biosimilar medications are less expensive versions of already approved biologic medications used for cancer, autoimmune, and other diseases. Although there can be some confusion by the public, biosimilars are actually different than generic versions of a brand-name drug.

Biosimilars are similar, but not identical, to the original medications – with the main attraction being cost savings without loss of effectiveness. Several oncology-related biosimilars are under review by the FDA this year.

The future looks brighter than ever for drug releases that can improve patient outcomes and quality of life.

As always, BioPlus Specialty Pharmacy is ready to partner with your office as the ‘fast & easy’ way to get your patients referred for the specialty medications they need.

Share this article

Share on facebook
Share on twitter
Share on linkedin
Share on email
Scroll to Top